(
out of
219
reviews
)
Clinical Locations
Primary Location
Sugar House Health Center
1280 E. Stringham Avenue
Salt Lake City
,
UT
84106
Board Certification
|
American Board of Internal Medicine (Internal Medicine)
American Board of Internal Medicine (Internal Medicine)
American Board of Internal Medicine (Sub: Hematology)
American Board of Internal Medicine (Sub: Hematology)
Educational Commission for Foreign Medical Graduates
Licentiate of the Medical Council of Canada
Royal College of Physicians and Surgeons of Canada
Royal College of Surgeons of Canada
|
Patient Rating
Patients repeatedly report that Dr. Parker is knowledgeable, communicates clearly, and takes time to listen and answer questions, leaving them feeling understood and confident in their care. Reviewers describe him as kind, calm, and attentive, with explanations and follow-up instructions that are straightforward and easy to understand. Many comments also praise the courteous, caring office staff and the overall quality of visits.
Generated via Patient Reviews
4.8
/5
( out of
219 reviews
)
The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers. The scale on which responses are measured is 1 to 5 with 5 being the best score.
Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.
Board Certification and Academic Information
| Academic Departments |
Internal Medicine
-Professor |
|---|---|
| Academic Divisions |
Hematology & Hematologic Malignancies
|
| Board Certification |
American Board of Internal Medicine (Internal Medicine)
American Board of Internal Medicine (Internal Medicine)
American Board of Internal Medicine (Sub: Hematology)
American Board of Internal Medicine (Sub: Hematology)
Educational Commission for Foreign Medical Graduates
Licentiate of the Medical Council of Canada
Royal College of Physicians and Surgeons of Canada
Royal College of Surgeons of Canada
|
Education history
| Fellowship | Hematology/Oncology - Duke University Medical Center | Fellow |
|---|---|---|
| Residency | Internal Medicine - North Carolina Memorial Hospital | Resident |
| Internship | North Carolina Memorial Hospital | Intern |
| Professional Medical | Medicine - University of North Carolina | M.D. |
| Undergraduate | English - University of North Carolina | A.B. |
Selected Publications
Journal Article
- Everhardt T, Julian K, Benefield R, Wilson A, Wilson N, Parker CJ, Parks A, Gilreath JA (2025). Platelet response following dexamethasone in obese vs nonobese patients with primary, acute immune-mediated thrombocytopenia. Res Pract Thromb Haemost, 9(3), 102844.
- Balwani M, Bonkovsky HL, Levy C, Anderson KE, Bissell DM, Parker C, Takahashi F, Desnick RJ, Belongie K, Endeavor Investigators (2023). Dersimelagon in Erythropoietic Protoporphyrias. N Engl J Med, 388(15), 1376-1385.
- Tantravahi SK, Huber BD, Vagher J, Maese L, Pomicter AD, Al-Sweel N, Asch JD, Toydemir RM, Hong B, Parker C (2022). Genome-wide uniparental disomy as a mechanism of immune escape in acquired aplastic anaemia. Br J Haematol, 198(6), e78-e81.
- Ventura P, Bonkovsky HL, Gouya L, Aguilera-Peir P, Montgomery Bissell D, Stein PE, Balwani M, Anderson DKE, Parker C, Kuter DJ, Monroy S, Oh J, Ritchie B, Ko JJ, Hua Z, Sweetser MT, Sardh E, ENVISION Investigators (2021). Efficacy and safety of givosiran for acute hepatic porphyria: 24-month interim analysis of the randomized phase 3 ENVISION study. Liver Int, 42(1), 161-172.
- Farrell CP, Nicolas G, Desnick RJ, Parker CJ, Lamoril J, Gouya L, Karim Z, Tchernitchko D, Chen B, Puy H, Phillips JD (2021). ABCB6 Polymorphisms are not Overly Represented in Patients with Porphyria. Blood Adv.
- Abou-Ismail MY, Prchal JT, Deininger MW, Parker CJ, Lim MY (2021). Anticoagulation management post-transjugular intrahepatic portosystemic shunt in portal hypertension associated with myeloproliferative neoplasms. Blood Coagul Fibrinolysis, 32(8), 578-583.
- Thiagarajan P, Parker CJ, Prchal JT (2021). How Do Red Blood Cells Die? Front Physiol, 12, 655393.
- Parker CJ, Desnick RJ, Bissel MD, Bloomer JR, Singal A, Gouya L, Puy H, Anderson KE, Balwani M, Phillips JD (2019). Results of a pilot study of isoniazid in patients with erythropoietic protoporphyria. Mol Genet Metab, 128(3), 309-313.
- Langendonk JG, Balwani M, Anderson KE, Bonkovsky HL, Anstey AV, Bissell DM, Bloomer J, Edwards C, Neumann NJ, Parker C, Phillips JD, Lim HW, Hamzavi I, Deybach JC, Kauppinen R, Rhodes LE, Frank J, Murphy GM, Karstens FPJ, Sijbrands EJG, de Rooij FWM, Lebwohl M, Naik H, Goding CR, Wilson JHP, Desnick RJ (2015). Afamelanotide for Erythropoietic Protoporphyria. N Engl J Med, 373(1), 48-59.
- Singal AK, Parker C, Bowden C, Thapar M, Liu L, McGuire BM (2014). Liver transplantation in the management of porphyria. Hepatology, 60(3), 1082-9.
- Swierczek SI, Piterkova L, Jelinek J, Agarwal N, Hammoud S, Wilson A, Hickman K, Parker CJ, Cairns BR, Prchal JT (2012). Methylation of AR locus does not always reflect X chromosome inactivation state. Blood, 119(13), e100-9.
- Ahmed KB, Warner SL, Chen A, Gourley ES, Liu X, Vankayalapati H, Nussenzveig R, Prchal JT, Bearss DJ, Parker CJ (2010). In vitro and in vivo characterization of SGI-1252, a small molecule inhibitor of JAK2. Exp Hematol, 39(1), 14-25.
- Parker CJ, Brodsky RA, Levine JE (2009). Treatment versus transplant for challenging hematologic disorders. Biol Blood Marrow Transplant, 15(1 Suppl), 72-8.
- Parker CJ, Janatova J, Weis JH (2000). Preface. Immunopharmacology, 49(1-2), 99-100.
- Bohnsack JF, Widjaja K, Ghazizadeh S, Rubens CE, Hillyard DR, Parker CJ, Albertine KH, Hill HR (1997). A role for C5 and C5a-ase in the acute neutrophil response to group B streptococcal infections. J Infect Dis, 175(4), 847-55.
- Liu L, Murray DK, Dameron CT, Parker CJ, Rodgers GM (1997). Biochemical characterization of procoagulant albumin. Thromb Res, 85(5), 399-411.
- Gubler DB, Ahlstrom CR, Liu L, Zhou JF, Parker CJ, Rodgers GM (1995). Procoagulant albumin increases vascular endothelial cell prostacyclin secretion. Thromb Haemost, 74(6), 1573-7.
- Grosset A, Liu L, Parker CJ, Rodgers GM (1994). Bioassay of procoagulant albumin in human plasma. Thromb Res, 75(5), 551-8.
- Tomita A, Radike EL, Parker CJ (1993). Isolation of erythrocyte membrane inhibitor of reactive lysis type II. Identification as glycophorin A. J Immunol, 151(6), 3308-23.
- Gubler DB, Wilson BD, Parker CJ, Rodgers GM (1993). Regulation of endothelial cell protein C activation and fibrinolysis by procoagulant albumin. Thromb Res, 70(6), 459-69.
- Ezzell JL, Parker CJ (1992). Cell-surface regulation of the human alternative pathway of complement. Sheep but not rabbit erythrocytes express factor I-dependent cofactor activity. Scand J Immunol, 36(1), 79-87.
- Bohnsack JF, Zhou XN, Gustin JN, Rubens CE, Parker CJ, Hill HR (1992). Bacterial evasion of the antibody response: human IgG antibodies neutralize soluble but not bacteria-associated group B streptococcal C5a-ase. J Infect Dis, 165(2), 315-21.
- Holguin MH, Martin CB, Bernshaw NJ, Parker CJ (1992). Analysis of the effects of activation of the alternative pathway of complement on erythrocytes with an isolated deficiency of decay accelerating factor. J Immunol, 148(2), 498-502.
- Bohnsack JF, Zhou XN, Williams PA, Cleary PP, Parker CJ, Hill HR (1991). Purification of the proteinase from group B streptococci that inactivates human C5a. Biochim Biophys Acta, 1079(2), 222-8.
- Janatova J, Cheung AK, Parker CJ (1991). Biomedical polymers differ in their capacity to activate complement. Complement Inflamm, 8(2), 61-9.
- Lassiter HA, Speranza MJ, Hall RT, Meade V, Christensen RD, Parker CJ (1990). Complement C3 deposition onto bacteria by neonatal serum is not enhanced after the infusion of intravenous immunoglobulin. J Perinatol, 10(1), 27-31.
- Parker CJ, Bernshaw NJ, Wilcox LA (1990). Analysis of the binding of human C3b to glycoproteins on rabbit and sheep erythrocytes. Complement Inflamm, 7(1), 1-17.
- Cheung AK, Parker CJ, Wilcox L (1989). Effects of two types of cobra venom factor on porcine complement activation and pulmonary artery pressure. Clin Exp Immunol, 78(2), 299-306.
- Lassiter HA, Christensen RD, Parker CJ (1989). Immunologic regulation of E. coli K1 by serum from neonatal rats is enhanced following intraperitoneal administration of human IgG. J Infect Dis, 159(3), 518-25.
- Parker CJ, Stone OL, Bernshaw NJ (1989). Characterization of the enhanced susceptibility of paroxysmal nocturnal hemoglobinuria erythrocytes to complement-mediated hemolysis initiated by cobra venom factor. J Immunol, 142(1), 208-16.
- Hill HR, Bohnsack JF, Morris EZ, Augustine NH, Parker CJ, Cleary PP, Wu JT (1988). Group B streptococci inhibit the chemotactic activity of the fifth component of complement. J Immunol, 141(10), 3551-6.
- Whatley RE, Lewis MS, Zimmerman GA, McIntyre TM, Parker CJ, Stevens DL, Prescott SM (1988). The regulation of synthesis of platelet-activating factor by endothelial cells. Chest, 93(3 Suppl), 110S-111S.
Review
- Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, Barton JC, Parker CJ (1993). HFE-Related Hemochromatosis. [Review]. Gene Reviews.
- Parker CJ (2012). Paroxysmal nocturnal hemoglobinuria. [Review]. Curr Opin Hematol, 19(3), 141-8.
- Parker CJ (2011). Management of paroxysmal nocturnal hemoglobinuria in the era of complement inhibitory therapy. [Review]. Hematology Am Soc Hematol Educ Program, 2011, 21-9.
- Parker, CJ (2011). Complement and hematology. [Review]. 8(1), 5.
Book Chapter
- Parker CJ (2017). Complement and PNH. In Kanakura Y, Kinoshita T, Nishimura J (Eds.), Paroxysmal Nocturnal Hemoglobinuria: From Bench to Bedside (pp. 67-98). Tokyo: Springer Japan KK.
- Parker CJ (2015). Paroxysmal Nocturnal Hemoglobinuria. In Kaushansky K, Lichtman M, Kipps T, Prchal J, Seligsohn U (Eds.), Williams Hematology (9th Edition). Boston: McGraw-Hill.
- Parker CJ (2015). Complement for the Clinician. In Brodsky R (Ed.), Complement-mediated Hemolytic Anemias, An Issue of Hematology/Oncology Clinics of North America. Philadelphia: Elsevier.
- Parker CJ, Ware RE (2014). Paroxysmal Nocturnal Hemoglobinuria. In Orkin S, Nathan G, Ginsburg D, Look AT, Fisher D, Lux S (Eds.), Nathan and Oski's Hematology and Oncology of Infancy and Childhood (8th Edition). Philadelphia: Elsevier.
- Parker, CJ and Ware, RE (2013). Paroxysmal nocturnal hemoglobinuria. In Greer J, Arber D, Glader B, List A, Means R, Paraskevas F, Rodgers G, Foerster J (Eds.), Wintrobe's Clinical Hematology (13th Ed, pp. 785-808). Philadelphia: Lippincott Williams & Wilkins.
Letter
- Tombul Z, Bahaj W, Ozturk M, Patel B, Toprak A, Ibrahim I, Chen W, Fuda F, Ogbue OD, Gurnari C, Parker C, Young NS, Maciejewski JP, Duran M, Bat T (2024). Ahemolytic PNH (white cell PNH): Clinical features and implications of a distinct phenotype of paroxysmal nocturnal haemoglobinuria. [Letter to the editor]. Br J Haematol, 204(5), 2121-2124.
- Trunk AD, Shewan SK, Lee CJ, Parker CJ, Couriel DR (2022). Chronic graft-versus-host disease exacerbation after SARS-CoV-2 vaccination. [Letter to the editor]. Bone Marrow Transplant, 57(3), 502-503.
Dr. Parker is very kind. He is very knowledgeable and I feel confident in his ability to treat my health concerns. I'm thankful to have him as my doctor
Professionally cordial.
Great Doctor & Staff- very attentive & Caring, Thank you.
Good experience [TRANSLATED]
Dr. Parker is a highly knowledgeable practitioner who is low key and informative. His explanations and instructions are straightforward and understandable.
I find Dr. Parker VERY good to work with. His demeanor is very soothing, open and helpful.
Dr. Parker was most attentive and knowledgeable about my condition. He gave me a generous amount of his time to explain his plan of care for me.
He is very professional [TRANSLATED]
Dr Parker is an excellent doctor. Very knowledgeable and caring.
Caring & knowledgeable.
I would not recommend this dr.
Clear, concise. Follow up
Dr Charles Parker is amazing !! He is not only very knowledgable but also very kind and personal. Very lucky to have him as my doctor.
Dr. Parker is kind and attentive. I've been a patient of his practice for almost 3 years. I'm grateful for their concern for me and my health.
I do not how to answer this question, just had a very brief meeting. He explain about the other blood test.
Very courteous Dr, who explained everything about my blood test certainly assured me that I was doing well and he would like to see me in a year his staff we're all very courteous
Tough to get an appointment, but worth the wait.
Good professional [TRANSLATED]
Outstanding
Dr. Parker is a down to earth physician. He explains things in easily understood terms. He listens to my concerns and answers clearly. He is calm and makes me at ease.
It is easy to tell that Dr. Parker cares about me and all his patients.
He is such a kind doctor and very thorough with all my health needs
Dr Parker was easy to understand. He explained his thoughts in a manner I could understand.